Arrowhead Pharmaceuticals Corp Stock Total Debt
| 0HI3 Stock | 18.55 0.04 0.22% |
Arrowhead Pharmaceuticals Corp fundamentals help investors to digest information that contributes to Arrowhead Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Arrowhead Stock. The fundamental analysis module provides a way to measure Arrowhead Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Arrowhead Pharmaceuticals stock.
Arrowhead |
Arrowhead Pharmaceuticals Corp Company Total Debt Analysis
Arrowhead Pharmaceuticals' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Arrowhead Pharmaceuticals Total Debt | 115.17 M |
Most of Arrowhead Pharmaceuticals' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arrowhead Pharmaceuticals Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Arrowhead Pharmaceuticals Corp has a Total Debt of 115.17 M. This is 94.07% lower than that of the Commercial Services & Supplies sector and significantly higher than that of the Industrials industry. The total debt for all United Kingdom stocks is 97.83% higher than that of the company.
Arrowhead Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arrowhead Pharmaceuticals' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arrowhead Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Arrowhead Pharmaceuticals by comparing valuation metrics of similar companies.Arrowhead Pharmaceuticals is currently under evaluation in total debt category among its peers.
Arrowhead Fundamentals
| Return On Equity | -1.52 | |||
| Return On Asset | -0.41 | |||
| Operating Margin | (27.85) % | |||
| Current Valuation | 2.34 B | |||
| Shares Outstanding | 88.02 M | |||
| Shares Owned By Insiders | 4.46 % | |||
| Shares Owned By Institutions | 79.60 % | |||
| Price To Sales | 92.86 X | |||
| Revenue | 240.74 M | |||
| Gross Profit | 240.74 M | |||
| EBITDA | (175.67 M) | |||
| Net Income | (209.28 M) | |||
| Total Debt | 115.17 M | |||
| Book Value Per Share | 2.66 X | |||
| Cash Flow From Operations | (153.89 M) | |||
| Earnings Per Share | (1.07) X | |||
| Number Of Employees | 525 | |||
| Beta | 0.93 | |||
| Market Capitalization | 182.46 B | |||
| Total Asset | 765.55 M | |||
| Retained Earnings | (1.03 B) | |||
| Net Asset | 765.55 M |
About Arrowhead Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arrowhead Pharmaceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arrowhead Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arrowhead Pharmaceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.